AR036237A1 - Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento - Google Patents

Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento

Info

Publication number
AR036237A1
AR036237A1 ARP020102731A ARP020102731A AR036237A1 AR 036237 A1 AR036237 A1 AR 036237A1 AR P020102731 A ARP020102731 A AR P020102731A AR P020102731 A ARP020102731 A AR P020102731A AR 036237 A1 AR036237 A1 AR 036237A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkyl
phenyl
tetrazolyl
Prior art date
Application number
ARP020102731A
Other languages
English (en)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR036237A1 publication Critical patent/AR036237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C07C51/44—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation by distillation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Derivados de ácido indan acético, que comprenden un compuesto de la fórmula (1), en la cual R es H ó alquilo C1-6; R1 es H, COOR, cicloalquilo C3-8, ó alquilo C1-6, alquenilo C2-6, ó alcoxi C1-6 cada uno de los cuales puede ser insustituido ó sustituido con flúor, metilendioxifenilo, ó fenilo que puede estar insustituido ó sustituido con R6; R2 es H, halo, ó alquilo C1-6 el cual puede estar insustituido ó sustituido con alcoxi C1-6, oxo, flúor, ó R2 es fenilo, furilo, tienilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, pirazolilo, isoxazolilo, isotiazolilo, triazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, piridilo, pirrolidinilo, piperidinilo, tetrahidropiranilo, tetrahidrotiopiranilo, piperazinilo, ó morfolinilo, cada uno de los cuales puede estar insustituido ó sustituido con R6; R3 es H, alquilo C1-6, ó fenilo que puede estar insustituido ó sustituido con R6; X es O ó S; R4 es alquilo C1-6 ó cicloalquilo C3-8, cualquiera de los cuales puede estar insustituido ó sustituido con flúor, oxo, ó alcoxi C1-6 que puede estar insustituido ó sustituido con alcoxi C1-6, ó fenilo sustituido en forma opcional con R6, ó cualquiera de los cuales puede estar sustituido con fenilo, naftilo, furilo, tienilo, pirrolilo, tetrahidrofurilo, pirrolidinilo, pirrolinilo, tetrahidrotienilo, oxazolilo, tiazolilo, imidazolilo, pirazolilo, isoxazolilo, isotiazolilo, triazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, piridilo, piperidinilo, tetrahidropiranilo, tetrahidrotiopiranilo, pirimidinilo, pirazinilo, piridazinilo, piperazinilo, morfolinilo, benzofurilo, dihidrobenzofurilo, benzotienilo, dihidrobenzotienilo, indolilo, indolinilo, indazolilo, benzoxazolilo, benzotiazolilo, bencimidazolilo, bencisoxazolilo, bencisotiazolilo, benzodioxolilo, quinolilo, isoquinolilo, quinazolinilo, quinoxazolinilo, dihidrobenzopiranilo, dihidrobenzotiopiranilo, ó 1,4-benzodioxanilo, cada uno de los cuales puede estar insustituido ó sustituido con R6, ó el alquilo C1-6 puede estar sustituido, además, con cicloalquilo C3-8 ó con fenoxi que puede estar insustituido ó sustituido con R6 ó con fenilo, naftilo, furilo, tienilo, pirrolilo, tetrahidrofurilo, pirrolidinilo, pirrolinilo, tetrahidrotienilo, oxazolilo, tiazolilo, imidazolilo, pirazolilo, isoxazolilo, isotiazolilo, triazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, piridilo, piperidinilo, tetrahidropiranilo, tetrahidrotiopiranilo, pirimidinilo, pirazinilo, piridazinilo, piperazinilo, morfolinilo, benzofurilo, dihidrobenzofurilo, benzotienilo, dihidrobenzotienilo, indolilo, indolinilo, indazolilo, benzoxazolilo, benzotiazolilo, bencimidazolilo, bencisoxazolilo, bencisotiazolilo, benzodioxolilo, quinolilo, isoquinolilo, quinazolinilo, quinoxazolinilo, dihidrobenzopiranilo, dihidrobenzotiopiranilo, ó 1, 4-benzodioxanilo, cada uno de los cuales puede estar insustituido ó sustituido con R6, o R4 es fenilo, naftilo, furilo, tienilo, pirrolilo, tetrahidrofurilo, pirrolidinilo, pirrolinilo, tetrahidrotienilo, oxazolilo, tiazolilo, imidazolilo, pirazolilo, isoxazolilo, isotiazolilo, triazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, piridilo, piperidinilo, tetrahidropiranilo, tetrahidrotiopiranilo, pirimidinilo, pirazinilo, piridazinilo, piperazinilo, morfolinilo, benzofurilo, dihidrobenzofurilo, benzotienilo, dihidrobenzotienilo, indolilo, indolinilo, indazolilo, benzoxazolilo, benzotiazolilo, bencimidazolilo, bencisoxazolilo, bencisotiazolilo, benzodioxolilo, quinolilo, isoquinolilo, quinazolinilo, quinoxazolinilo, dihidrobenzopiranilo, dihidrobenzotiopiranilo, ó 1, 4-benzodioxanilo, cada uno de los cuales puede estar insustituido ó sustituido con R6, ó con fenilo, furilo, tienilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, pirazolilo, isoxazolilo, isotiazolilo, triazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, piridilo, pirrolidinilo, piperidinilo, tetrahidropiranilo, tetrahidrotiopiranilo, piperazinilo, morfolinilo, benzodioxolilo, dihidrobenzofuranilo, indolilo, pirimidinilo ó fenoxi, cada uno de los cuales puede estar insustituido ó sustituido con R6; R5 es H, halo ó alquilo C1-6 sustituido en forma opcional con oxo; R6 es halo, CF3, alquilo C1-6 sustituido en forma opcional con oxo ó hidroxi, ó alcoxi C1-6 sustituido en forma opcional con flúor; y sus sales y ésteres aceptables par uso farmacéutico; intermediarios y método para su preparación, composición farmacéutica y uso de dichos derivados para la manufactura de un medicamento que son útiles en el tratamiento de enfermedades como la diabetes, la obesidad, la hiperlipidemia y la enfermedad ateroesclerótica.
ARP020102731A 2001-07-27 2002-07-19 Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento AR036237A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30850001P 2001-07-27 2001-07-27
US37304802P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
AR036237A1 true AR036237A1 (es) 2004-08-25

Family

ID=26976280

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102731A AR036237A1 (es) 2001-07-27 2002-07-19 Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento

Country Status (32)

Country Link
US (4) US6828335B2 (es)
EP (1) EP1414809B1 (es)
JP (1) JP4510447B2 (es)
KR (2) KR100956898B1 (es)
CN (1) CN100528850C (es)
AR (1) AR036237A1 (es)
AT (1) ATE388944T1 (es)
AU (2) AU2002319693B2 (es)
BR (1) BR0211502A (es)
CA (2) CA2455620C (es)
CO (1) CO5560561A2 (es)
CY (1) CY1107370T1 (es)
DE (1) DE60225561T2 (es)
DK (1) DK1414809T3 (es)
ES (1) ES2302825T3 (es)
HR (1) HRP20040076A2 (es)
HU (1) HUP0700105A2 (es)
IL (3) IL159960A0 (es)
MA (1) MA27063A1 (es)
MX (1) MXPA04000599A (es)
MY (1) MY139541A (es)
NO (2) NO20040356L (es)
NZ (1) NZ531351A (es)
PE (1) PE20030326A1 (es)
PL (1) PL374383A1 (es)
PT (1) PT1414809E (es)
RU (1) RU2314298C2 (es)
SI (1) SI1414809T1 (es)
SV (1) SV2003001186A (es)
TW (2) TWI328008B (es)
UY (1) UY27392A1 (es)
WO (1) WO2003011842A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US20110065129A1 (en) * 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AU2003263814A1 (en) * 2002-07-26 2004-02-16 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
CA2510793A1 (en) * 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
JPWO2005110394A1 (ja) * 2004-05-19 2008-03-21 味の素株式会社 糖尿病治療薬
JP2008510696A (ja) * 2004-08-20 2008-04-10 カディラ ヘルスケア リミティド 新規抗糖尿病化合物
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
TWI330639B (en) * 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
EP2006271A4 (en) 2006-03-30 2011-08-10 Asahi Kasei Pharma Corp SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF
GB0712653D0 (en) 2007-06-28 2007-08-08 Syngenta Ltd Novel herbicides
GB0717082D0 (en) 2007-09-03 2007-10-10 Syngenta Ltd Novel herbicides
EP2272832A4 (en) 2008-04-28 2011-09-07 Asahi Kasei Pharma Corp PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF
RU2504363C2 (ru) * 2008-06-23 2014-01-20 Тоа Эйо Лтд. Усилитель чрескожного всасывания и трансдермальный препарат с его использованием
EA022417B1 (ru) * 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
WO2010085811A2 (en) * 2009-01-26 2010-07-29 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
AR075401A1 (es) * 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
US20180200230A1 (en) * 2009-06-04 2018-07-19 Dara Biosciences, Inc. Methods of treating neurodegenerative diseases using indane acetic acid derivatives which penetrate the blood brain barrier
WO2010141696A1 (en) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
WO2010141690A2 (en) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Indane analogs and use as pharmaceutical agents and process of making
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
WO2012074980A2 (en) * 2010-12-01 2012-06-07 Dara Biosciences, Inc. Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
HK1248537A1 (zh) * 2015-03-26 2018-10-19 T3D治疗有限责任公司 使用茚满乙酸衍生物治疗肝病的方法
TWI712582B (zh) * 2015-10-14 2020-12-11 法商領先藥物公司 用來製備(5s,10s)-10-苄基-16-甲基-11,14,18-三側氧基-15,17,19-三氧雜-2,7,8-三噻基-12-氮二十一烷基-5-銨基(e)-3-羧基丙烯酸鹽的工業方法
US20180153860A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
WO2020064173A1 (en) 2018-09-25 2020-04-02 Antabio Sas Indane derivatives for use in the treatment of bacterial infection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929923A (en) * 1972-01-17 1975-12-30 Sun Research Development Process for preparation of isomers of 1-cyclohexyl-1,3,3-trimethylhydrindane
US4754043A (en) * 1985-10-03 1988-06-28 American Home Products Corporation Oxazole and thiazole naphthalenes as antiallergic agents
FR2670491B1 (fr) * 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
JPH1087602A (ja) * 1996-09-09 1998-04-07 Zeria Pharmaceut Co Ltd スルホンアミド誘導体、それを含有するトロンボキサン拮抗剤及び該化合物の製造中間体
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
NZ515087A (en) 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
WO2001016120A1 (en) * 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
CA2420178A1 (en) * 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento

Also Published As

Publication number Publication date
WO2003011842A1 (en) 2003-02-13
HRP20040076A2 (en) 2005-06-30
HUP0700105A2 (en) 2007-09-28
NZ531351A (en) 2006-09-29
US20060205723A1 (en) 2006-09-14
CA2753329A1 (en) 2003-02-13
HK1098125A1 (zh) 2007-07-13
CA2455620A1 (en) 2003-02-13
IL208891A (en) 2013-02-28
TWI345563B (en) 2011-07-21
CN1558905A (zh) 2004-12-29
TW201029979A (en) 2010-08-16
DE60225561T2 (de) 2009-04-23
KR100987267B1 (ko) 2010-10-12
RU2004105925A (ru) 2005-07-10
US20030216391A1 (en) 2003-11-20
US7358386B2 (en) 2008-04-15
PL374383A1 (en) 2005-10-17
US7112597B2 (en) 2006-09-26
IL159960A0 (en) 2004-06-20
NO20040356L (no) 2004-03-19
KR20090125225A (ko) 2009-12-03
MA27063A1 (fr) 2004-12-20
US6828335B2 (en) 2004-12-07
US20050075338A1 (en) 2005-04-07
DE60225561D1 (de) 2008-04-24
RU2314298C2 (ru) 2008-01-10
ES2302825T3 (es) 2008-08-01
JP4510447B2 (ja) 2010-07-21
SV2003001186A (es) 2003-03-18
CY1107370T1 (el) 2012-12-19
SI1414809T1 (sl) 2008-08-31
KR100956898B1 (ko) 2010-05-11
US20090047687A1 (en) 2009-02-19
JP2005508308A (ja) 2005-03-31
IL159960A (en) 2010-12-30
EP1414809A1 (en) 2004-05-06
HK1073653A1 (zh) 2005-10-14
MXPA04000599A (es) 2005-02-17
MY139541A (en) 2009-10-30
CN100528850C (zh) 2009-08-19
AU2008237581A1 (en) 2008-11-20
UY27392A1 (es) 2003-01-31
IL208891A0 (en) 2011-01-31
CA2455620C (en) 2011-12-06
AU2002319693B2 (en) 2008-08-07
CO5560561A2 (es) 2005-09-30
PE20030326A1 (es) 2003-04-16
KR20040028950A (ko) 2004-04-03
BR0211502A (pt) 2005-09-20
ATE388944T1 (de) 2008-03-15
TWI328008B (en) 2010-08-01
EP1414809B1 (en) 2008-03-12
NO20083411L (no) 2004-03-19
PT1414809E (pt) 2008-06-04
DK1414809T3 (da) 2008-06-23

Similar Documents

Publication Publication Date Title
CO5560561A2 (es) Derivados de acido indan acetico y su uso como agentes farmaceuticos, intermediarios, y metodo de preparacion
CL2021000645A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
BR0308681A (pt) Métodos de fabricação de derivados de ácido beta-hidroxicarboxìlico
AR043210A1 (es) Compuestos de triazol utiles en terapia
MX9703687A (es) Nuevas bencil pirimidinas.
AR036813A1 (es) Composiciones farmaceuticas
GT200900194A (es) Derivados de espirocromanona sustituida como inhibidores de acc.
AR061666A1 (es) Derivados de bencimidazol, metodo de produccion de los mismos y preparaciones farmaceuticas que los contienen
DK1506159T3 (da) Fremgangsmåde til fremstilling af 2-(4-N,N-diethylamino-2-hydroxybenzoyl)benzoesyre-n-hexyl-ester
JP2015529229A5 (es)
ECSP066371A (es) 2,4-pirimidinadiaminas útiles en el tratamiento de enfermedades neoplásicas, desórdenes del sistema inmune e inflamatorios
JP2008519847A5 (es)
GB1138590A (en) Visual display device
BRPI0415085A (pt) catalisador adequado para uso em uma reação de esterificação, processo para produção de um éster e processo para produção de um poliéster
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
Rodriguez et al. First total synthesis of the macrophage derived anti-inflammatory and pro-resolving lipid mediator Maresin 2
EP0335164A3 (de) Neopentylesterderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
Abe et al. Enantioselective synthesis of valoneic acid derivative
FI903905A7 (fi) Menetelmä uusien estereiden, ja niiden suolojen, valmistamiseksi orgaanisista hapoista 19-nor-steroidien alkoholijohdannaisten kanssa
AR061623A1 (es) Derivados de acido fenilacetico
FR2387211A1 (fr) Preparation d'esters de l'alcool m-phenoxybenzylique
BR0108251A (pt) Derivado de pirrolopiridazina ou um sal deste farmaceuticamente aceitável, composição farmacêutica, agente contendo um derivado de pirrolopiridazina ou um sal deste farmaceuticamente aceitável, e, uso de um derivado de pirrolopiridazina ou um sal deste farmaceuticamente aceitável
Karim et al. Transannular aldol condensations within macrocyclic lactones: A novel approach to 8-membered carbocyclic rings.
AR038029A1 (es) Derivados de benzotiazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ATE90095T1 (de) Optisch aktive produkte von 20,21dinoreburnamenin-derivaten,verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure